Swiss National Bank’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.18M | Buy |
93,800
+6,900
| +8% | +$381K | ﹤0.01% | 1272 |
|
|
2025
Q1 | $4.2M | Hold |
86,900
| – | – | ﹤0.01% | 1357 |
|
|
2024
Q4 | $3.35M | Buy |
86,900
+1,000
| +1% | +$38.6K | ﹤0.01% | 1544 |
|
|
2024
Q3 | $3.87M | Hold |
85,900
| – | – | ﹤0.01% | 1481 |
|
|
2024
Q2 | $2.98M | Sell |
85,900
-4,800
| -5% | -$166K | ﹤0.01% | 1598 |
|
|
2024
Q1 | $2.62M | Hold |
90,700
| – | – | ﹤0.01% | 1689 |
|
|
2023
Q4 | $2.08M | Sell |
90,700
-9,900
| -10% | -$227K | ﹤0.01% | 1803 |
|
|
2023
Q3 | $1.68M | Buy |
100,600
+2,600
| +3% | +$43.4K | ﹤0.01% | 1951 |
|
|
2023
Q2 | $2.71M | Buy |
98,000
+18,300
| +23% | +$505K | ﹤0.01% | 1691 |
|
|
2023
Q1 | $1.83M | Sell |
79,700
-9,200
| -10% | -$212K | ﹤0.01% | 1887 |
|
|
2022
Q4 | $970K | Buy |
88,900
+2,400
| +3% | +$26.2K | ﹤0.01% | 2360 |
|
|
2022
Q3 | $729K | Buy |
86,500
+2,200
| +3% | +$18.5K | ﹤0.01% | 2454 |
|
|
2022
Q2 | $667K | Sell |
84,300
-17,200
| -17% | -$136K | ﹤0.01% | 2538 |
|
|
2022
Q1 | $2.4M | Buy |
101,500
+7,300
| +8% | +$173K | ﹤0.01% | 1926 |
|
|
2021
Q4 | $3.22M | Buy |
94,200
+6,800
| +8% | +$233K | ﹤0.01% | 1748 |
|
|
2021
Q3 | $1.55M | Buy |
87,400
+600
| +0.7% | +$10.6K | ﹤0.01% | 2209 |
|
|
2021
Q2 | $3.9M | Buy |
86,800
+3,200
| +4% | +$144K | ﹤0.01% | 1671 |
|
|
2021
Q1 | $2.17M | Buy |
83,600
+900
| +1% | +$23.3K | ﹤0.01% | 1951 |
|
|
2020
Q4 | $1.67M | Buy |
+82,700
| New | +$1.67M | ﹤0.01% | 2012 |
|